首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   12339篇
  免费   1314篇
  国内免费   34篇
耳鼻咽喉   260篇
儿科学   361篇
妇产科学   291篇
基础医学   1626篇
口腔科学   333篇
临床医学   1490篇
内科学   2694篇
皮肤病学   187篇
神经病学   934篇
特种医学   409篇
外科学   1745篇
综合类   348篇
一般理论   7篇
预防医学   1296篇
眼科学   205篇
药学   883篇
中国医学   7篇
肿瘤学   611篇
  2021年   173篇
  2020年   133篇
  2019年   184篇
  2018年   188篇
  2017年   175篇
  2016年   151篇
  2015年   224篇
  2014年   253篇
  2013年   386篇
  2012年   532篇
  2011年   533篇
  2010年   281篇
  2009年   262篇
  2008年   463篇
  2007年   525篇
  2006年   495篇
  2005年   490篇
  2004年   476篇
  2003年   501篇
  2002年   450篇
  2001年   388篇
  2000年   466篇
  1999年   349篇
  1998年   157篇
  1997年   133篇
  1996年   136篇
  1995年   120篇
  1994年   115篇
  1993年   104篇
  1992年   295篇
  1991年   292篇
  1990年   264篇
  1989年   275篇
  1988年   224篇
  1987年   220篇
  1986年   257篇
  1985年   228篇
  1984年   188篇
  1983年   146篇
  1982年   127篇
  1979年   184篇
  1978年   117篇
  1977年   117篇
  1976年   100篇
  1975年   123篇
  1974年   145篇
  1973年   135篇
  1972年   141篇
  1971年   121篇
  1970年   110篇
排序方式: 共有10000条查询结果,搜索用时 818 毫秒
71.
利用乙型肝炎病毒DNA开放框架上的BamHI和HpaI位点,酶切消化质粒载体PEcob6(含双拷贝HBVDNA),得到约900bp的HBV-S基因片断。将其插入到噬菌粒载体PBluescriptsk+的SmaI位点上。然后通过体外寡核苷酸介导的人工定点突变获得一系列(共12种)S基因“免疫逃避”突变型。再通过EB病毒真核表达载体pMEP4上的BamHI和Kpnl位点将噬菌粒pBluescripsk+上的S基因突变型片断定向克隆到PMEP4上,从而构建了含乙肝S基因突变型的重组质粒pMEP4HBSM。用其转染人肝癌传代细胞系HepG2,经潮霉素选择,三周后获得抗性细胞克隆。经用抗HBs单克隆抗体(含针对HBsAg“a”抗原决定簇)检测除含变异体145(即145位上甘氨酸为精氨酸替代)外其余抗变异体HBsAg均为阳性。经Westernblot证实变异体145,在分子量约为23KD处有一特异HBsAg蛋白带。  相似文献   
72.
Background The relative proportions of fibrosis and inflammation seen by open lung biopsy examination is a predictor of disease outcome in fibrosing alveolitis. This study was designed to assess the ability of high resolution computed tomography to predict the histological appearance of open lung biopsy specimens from patients with systemic sclerosis.  相似文献   
73.
Urologists remain divided as to the need for routine irrigation following transurethral prostatectomy (TURP). This randomised prospective study compared a policy of irrigation with that of no irrigation in a consecutive group of 200 patients undergoing TURP. In the irrigation group, a mean of 15 litres of irrigating fluid was used in each patient and one-third of patients required at least one bladder washout. In the no irrigation group, although two-thirds of the patients required at least one bladder washout, only one-third required more than one washout. No significant difference in blood loss, electrolyte balance, infection rate or recovery was seen in the 2 groups. This study led to a local change in practice, converting from a policy of routine irrigation to one of no irrigation.  相似文献   
74.
75.
76.
77.
HEART BLOCK IN OSTEITIS DEFORMANS   总被引:1,自引:0,他引:1  
  相似文献   
78.
Pradeep J Nathan  Andrew H Kemp  Ben J Harrison 《Neuropsychopharmacology》2003,28(7):1383; author reply 1384-1383; author reply 1385
  相似文献   
79.
The authors investigated the ability of recombinant human gamma-interferon (rhIFN-gamma) to influence production of complement and expression of human leukocyte antigens (HLA) by human scleral fibroblasts in culture. Cell cultures were established by explanting sclera from normal human donor eyes. To study complement production, fibroblasts were treated with 500 units/ml rhIFN-gamma in cell culture, and media were tested for complement components by hemolytic assay after 0, 1, 3, 6, 9, and 11 days. To induce Class II HLAs, fibroblasts were exposed to rhIFN-gamma at concentrations ranging from 10-500 units/ml and incubated for 1, 3, and 6 days. The HLAs were detected by immunofluorescence in conjunction with flow cytometry. Class I antigen was detected using a monoclonal antibody directed against beta 2-microglobulin. Class II histocompatibility antigens were identified using monoclonal antibodies specific for HLA-DR, -DP, and -DQ. Although complement component C1 was produced constitutively in cell culture, the addition of rhIFN-gamma resulted in an increase in production. Complement components C2 and C4 were detected only after treatment with rhIFN-gamma. Complement production was completely inhibited by cycloheximide, and C3, C5, C6, and C7 were not present in cell culture media with or without rhIFN-gamma. Class I antigen was present on all cells before induction, and an increase in expression was noted after exposure to rhIFN-gamma. Class II antigens were absent before induction with rhIFN-gamma. After treatment with rhIFN-gamma, scleral fibroblasts expressed HLA-DR, -DP, and -DQ in a dose-dependent, time-related fashion. These findings suggest that rhIFN-gamma has multiple effects on scleral fibroblasts: (1) increased production of C1, (2) production of C2 and C4, (3) up-regulation of Class I antigen expression, and (4) expression of Class II antigens. They also suggest that scleral fibroblasts have the potential to participate in immunologic diseases of the eye.  相似文献   
80.
T2 relaxation makes an important contribution to tissue contrast in magnetic resonance (MR) imaging. Many tissues are known to exhibit multicomponent T2 relaxation that suggests some compartmental segregation of mobile protons on a T2 timescale. Magnetization transfer (MT) is another relaxation mechanism that can be used to produce tissue contrast in MR imaging. The MT process depends strongly on water-macromolecular interactions. To investigate the relationship between multicomponent T2 relaxation and the MT process, multiecho T2 measurements have been combined with MT measurements for freshly excised samples of cardiac muscle, striated muscle, and white matter. For muscle, short T2 components show greater MT than long T2 components, consistent with the belief that they represent distinct water environments. For white matter, quantitative MT measurements were identical for the two major T2 components, apparently because of exchange between the T2 compartments on a timescale characteristic of the MT experiment. Implications for accurate modeling of MT in tissue and the use of MT for MR image contrast are discussed.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号